# Aspire-Lakewood Holdings, Inc.: overview

ASBP · Nasdaq · CIK 1847345 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/asbp.md) · [Financials](/companies/asbp/financials.md) · [Filings](/companies/asbp/filings.md) · [Insiders](/companies/asbp/insiders.md)

Latest reported revenue: [$63.1k](/filings/0001493152-26-037819.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 13, 2026 (XBRL us-gaap:Revenues, accession 0001493152-26-037819).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | [1.9](/filings/0001493152-25-023619.md) | [4.3 d](/filings/0001493152-26-015737.md) | [28.4](/filings/0001493152-26-023802.md) | [63.1](/filings/0001493152-26-037819.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | [45.5%](/filings/0001493152-25-023619.md) | [(23.5%) d](/filings/0001493152-26-015737.md) | [20.3%](/filings/0001493152-26-023802.md) | [(47.7%)](/filings/0001493152-26-037819.md) |
| Operating margin | % | not reported | not reported | not reported | not reported | [(59015.8%)](/filings/0001493152-25-023619.md) | [(43403.5%) d](/filings/0001493152-26-015737.md) | [(5806.0%)](/filings/0001493152-26-023802.md) | [(4244.1%)](/filings/0001493152-26-037819.md) |
| Net margin | % | not reported | not reported | not reported | not reported | [(95337.1%)](/filings/0001493152-25-023619.md) | [(110484.3%) d](/filings/0001493152-26-015737.md) | [(11367.0%)](/filings/0001493152-26-037819.md) | [(2009.6%)](/filings/0001493152-26-037819.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0001493152-25-023619.md) | not reported | [(504.88)](/filings/0001493152-26-023802.md) | [(48.19)](/filings/0001493152-26-037819.md) | [(0.04)](/filings/0001493152-25-023619.md) | not reported | [(20.57)](/filings/0001493152-26-023802.md) | [(1.22)](/filings/0001493152-26-037819.md) |
| Free cash flow | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $ | not reported | not reported | not reported | [6,202](/filings/0001493152-26-015737.md) |
| Gross margin | % | not reported | not reported | not reported | [(1.9%)](/filings/0001493152-26-015737.md) |
| Operating margin | % | not reported | not reported | not reported | [(312016.9%)](/filings/0001493152-26-015737.md) |
| Net margin | % | not reported | not reported | not reported | [(394725.1%)](/filings/0001493152-26-015737.md) |
| Diluted EPS | $ per share | not reported | not reported | [(1.90)](/filings/0001493152-26-015737.md) | [(16.38)](/filings/0001493152-26-015737.md) |
| Free cash flow | $ | not reported | not reported | not reported | not reported |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/asbp/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $79.2k | 14,830 |  | New +14,830 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $55.9k | 10,474 |  | New +10,474 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $55.6k | 10,408 |  | New +10,408 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $53.8k | 10,081 |  | New +10,081 |
| [Saba Capital Management, L.P.](/funds/1510281.md) | 2026-06-30 | $22.9k | 983,603 |  | Unchanged |
| [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $21.0k | 1,050,000 |  | Unchanged |
| [Linden Advisors LP](/funds/1279396.md) | 2026-06-30 | $21.0k | 899,999 |  | Unchanged |
| [ARISTEIA CAPITAL, L.L.C.](/funds/1080171.md) | 2026-06-30 | $15.9k | 681,516 |  | Unchanged |
| [TORONTO DOMINION BANK](/funds/947263.md) | 2026-06-30 | $10.3k | 516,245 |  | Reduced −100 |
| [Sculptor Capital LP](/funds/1054587.md) | 2026-06-30 | $10.0k | 500,000 |  | Unchanged |

## Recent filings

[All 224 filings](/companies/asbp/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-20 | 21:31 ET | [8-K/A](/filings/0001493152-26-047801.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001493152-26-047801 |
| 2026-09-29 | 21:15 ET | [8-K](/filings/0001493152-26-044908.md) | 4.01 Change of auditor; 9.01 Financial statements and exhibits | 0001493152-26-044908 |
| 2026-09-09 | 14:10 ET | [8-K](/filings/0001493152-26-041918.md) | 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-041918 |
| 2026-09-08 | 14:10 ET | [8-K](/filings/0001493152-26-041725.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-041725 |
| 2026-08-19 | 12:30 ET | [8-K](/filings/0001493152-26-039135.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-039135 |
| 2026-08-13 | 20:31 ET | [10-Q](/filings/0001493152-26-037819.md) | Quarterly report, period 2026-06-30 | 0001493152-26-037819 |
| 2026-08-10 | 13:45 ET | [8-K](/filings/0001493152-26-036777.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-036777 |
| 2026-07-20 | 21:20 ET | [8-K](/filings/0001493152-26-033942.md) | 8.01 Other events | 0001493152-26-033942 |
| 2026-06-22 | 20:35 ET | [8-K](/filings/0001493152-26-029599.md) | 5.07 Shareholder vote results | 0001493152-26-029599 |
| 2026-06-12 | 21:15 ET | [8-K](/filings/0001493152-26-028518.md) | 8.01 Other events | 0001493152-26-028518 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-013682.md), filed Mar 30, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/16deff56-2822-44ec-8b58-282c8d33f4e2)

## About the filer

- CIK: 1847345
- Tickers: ASBP, ASBPW
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: E9
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.